Please login to the form below

Not currently logged in
Email:
Password:

GSK vaccines business management shift

Jean Stephenne has been appointed as chairman of GlaxoSmithKline (GSK) Biologicals as part of GSK's planned succession strategy

Jean Stephenne has been appointed as chairman of GlaxoSmithKline (GSK) Biologicals as part of GSK's planned succession strategy.

Mr Stephenne will assume his new position with immediate effect while continuing in his current role as president, GSK Biologicals. Over the next two years operational responsibility for GSK Biologicals will move to Dr Moncef Slaoui, who continues in his current role as chairman of research and development. 

CEO of GSK, Andrew Witty, commented: "Succession planning is fundamental to GSK's long-term success and today's changes are clear evidence that we are taking proactive steps to maintain excellent leadership in our business. Jean has built a world-leading vaccines business and as chairman will continue to be instrumental in driving forward our public health agenda, while Moncef has more than 17 years experience working in the vaccines area and has played a critical role in developing the strong pipeline we have today."

According to Mr Witty, these changes to the business will ensure a continued focus on development and delivery of GSK's vaccine pipeline.

15th March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...